Tesamorelin

Scientific Overview

Tesamorelin is a stabilized GHRH analog studied and used clinically for reduction of excess visceral adipose tissue in HIV-associated lipodystrophy, with additional metabolic and hepatic-fat research.

Mechanism focus

Pulsatile GH release via GHRH receptor activation; visceral fat and liver-fat endpoints have been primary clinical research readouts.

Research Use Cases

• Visceral adiposity and body-composition research
• HIV lipodystrophy metabolic models
• Liver-fat / NAFLD-adjacent imaging endpoints
• GH axis therapeutics pharmacology

Use-Case Study Notations

• Case-study notation: randomized studies reported reductions in visceral and liver fat in HIV patients with abdominal fat accumulation.
• Case-study notation: newer work examines tesamorelin with modern antiretroviral regimens and neurocognitive outcomes.
• Present research-grade material separately from approved branded drug product.

Selected Studies

1. 01 Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulationPubMed 25038357
2. 02 Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophyPubMed 22298602
3. 03 Tesamorelin, a human growth hormone releasing factor analoguePubMed 19243281
4. 04 Efficacy and safety of tesamorelin in people with HIV on integrase inhibitorsPubMed 38905488
5. 05 Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal ObesityPubMed 39813152

Related compounds

Ipamorelin · CJC-1295 (DAC)